Immune cell therapy for adults with returning blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immune cell treatment for adults with a type of blood cancer (B-cell lymphoma) that has come back or not improved after standard treatments. The therapy uses specially engineered immune cells to target and destroy cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of B-cell lymphoma that has returned or not responded to at least two prior treatments.
- Your cancer cells must have a specific marker called CD19.
- You must be in reasonably good health, with adequate heart, kidney, and liver function.
- You must be willing to use effective birth control during treatment and for one year after.
- You must not have cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy using your own immune cells (gamma-delta T cells) that are engineered to find and kill cancer cells that carry a protein called CD19. It is for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new kind of immune cell therapy for people with certain types of lymphoma that have come back or not responded to previous treatments. The cells are made from your own blood and are designed to find and attack the cancer cells.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
Hear when a new Recurrent/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.